OBI Pharma, Inc. (TPEX:4174)

Taiwan · Delayed Price · Currency is TWD

38.55

+0.15 (0.39%)

At close: Mar 24, 2026

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Adjustments and Eliminations		-28.10M	-29.31M	-59.79M	-24.79M	-
New Anticancer Drug		3.37M	2.03M	2.00M	1.76M	-
New Anticancer Drug Growth		66.16%	1.40%	14.01%	-	-
CDMO		87.41M	68.83M	62.50M	34.81M	-
CDMO Growth		27.00%	10.13%	79.52%	-	-
New bispecific antibody drug		-	-	-	6.99M	-
New Drug Development		-	-	-	-	140.89M
New Drug Development Growth		-	-	-	-	2422.13%
Total		62.68M	41.55M	4.71M	18.77M	140.89M
Total Growth		50.85%	781.96%	-74.90%	-86.68%	2422.13%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Taiwan		60.68M	39.99M	3.43M	4.13M	3.33M
Taiwan Growth		51.74%	1065.18%	-16.92%	24.20%	-40.46%
Others		2.00M	1.56M	1.28M	14.64M	137.56M
Others Growth		28.14%	21.97%	-91.26%	-89.36%	-
Total		62.68M	41.55M	4.71M	18.77M	140.89M
Total Growth		50.85%	781.96%	-74.90%	-86.68%	2422.13%

Source: S&P Global Market Intelligence.